Evidence map›Paper›PMID 41917251›Full record

ArticleNPJ precision oncology2026

Habitat-based CT radiomics profiling spatial-temporal heterogeneity in resectable NSCLC predict pathological response to neoadjuvant chemoimmunotherapy: a multi-center study.

Qin Peng, Yanglan Xu, Leilei Shen, Xiao Bao, Shuchang Zhou, Xiaodan Ye, Yajia Gu, Jing Gong

Abstract read
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Qin Peng *Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yanglan Xu *Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.
Leilei ShenDepartment of Radiology, Shanghai Geriatric Medical Center, Shanghai, China.
Xiao BaoDepartment of Radiology, Shanghai Pulmonary Hospital, Shanghai, China.
Shuchang ZhouDepartment of Radiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiaodan YeDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China. yuanyxd@163.com.
Yajia GuDepartment of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China. cjr.guyajia@vip.163.com.
Jing GongDepartment of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China. gongjing1990@163.com.

Funding

the Excellent Young Talents Project of Shanghai Public Health Three-year (2023-2025) Action Plan No. GWVI-11.2-YQ48the National Natural Science Foundation of China No.82001785the National Natural Science Foundation of China No. 82001903the Natural Science Foundation of Shanghai No. 25ZR1402077
6 · The paper itself

Abstract

The profound spatial and temporal heterogeneity of non-small cell lung cancer (NSCLC) drives unpredictable responses to neoadjuvant chemoimmunotherapy (NCI), highlighting the need for effective predictive biomarkers to optimize treatment. In this multicenter study, we evaluated the ability of habitat imaging to predict major pathological response (MPR) to NCI by capturing spatial-temporal tumor heterogeneity, using pre- and post-treatment CT scans from 394 patients with resectable non-small cell lung cancer across three institutions. A radiomics-based predictive framework integrating global texture descriptors, spatial heterogeneity features, and longitudinal imaging information was constructed to distinguish pathological responders from non-responders. Models based on global texture or spatial heterogeneity features alone achieved areas under the receiver operating characteristic curve (AUCs) ranging from 0.71 to 0.80 across validation cohorts, whereas the integrated model further improved discrimination, achieving an AUC of up to 0.85 in external validation. These findings demonstrate that habitat imaging provides a robust approach for predicting MPR and supporting patient stratification and personalized treatment planning in NSCLC.

Identifiers

PMID41917251
PMCPMC13201635

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.